Researchers, including an IMES faculty member, argue that there is limited evidence of tumor mutational burden as a biomarker of response to immunotherapy. Immunotherapy is an effective cancer treatment, but only for less than half of all patients. This has led researchers to focus on ways to anticipate which patients…